RE:RE:RE:RE:RE: Annual General Meeting April 29because the market is discounting pharma value at this time, it is the best time in a number of years to be looking at product acquisitions as other companies [think vrx] divest some products at distressed prices to shore up the balance sheets. Given the now global presence of cxr, these products may have more value to cxr today than it had a year ago.
visionaryfool wrote:
yeah agreed. its all about the deal making ability of management. I know they've had some success but if they are able to get something accretive, they'll still need to show results to ensure it is accretive. Looking at the Covis portfolio, not all of it worked out but the AMCO one is doing great. Hopefully they are ablet to deliver on the new platform and then we will really see a rally.